German Court Found Dermatologist Liable for Failing to Warn Propecia Patient of Potentially Persistent Sexual Side Effects

Physician should have informed patient that sexual dysfunction could persist after finasteride was discontinued and could be ‘permanent or irreversible,’ three-judge panel ruled in recently obtained 2024 judgment

November 15, 2026

Dear Friends:

It was a shot that went unreported outside German judicial circles. Until now.

The Legal Blemish

On January 26, 2024, a three-judge panel at Mönchengladbach Regional Court found a dermatologist liable for failing to warn his Propecia patient that sexual dysfunction could persist after discontinuing the drug and could be “permanent or irreversible.” The patient had sought at least €100,000 in compensation.

The ruling (English), which established the clinician’s liability in principle but left the amount of damages to be determined in subsequent proceedings, centered on whether the dermatologist was obliged to warn his patient about potentially permanent sexual side effects despite uncertainty in the scientific evidence linking those effects to finasteride at the time the drug was prescribed.

Notably, a November 2, 2026, letter from the court obtained on behalf of the PFS Foundation confirms that the judgment was not legally final as of that date. Whether the dermatologist, who hadn’t responded to a request for comment at press time, appealed the ruling, reached an out-of-court settlement, or remains involved in ongoing litigation is unclear.

The judgment nonetheless appears to be the first civil court ruling worldwide to hold a physician liable for failing to warn a patient about potentially permanent sexual side effects of finasteride.

The Whistle Whisperers

In September of this year, thousands of miles from Mönchengladbach, a woman involved in a separate Propecia lawsuit was researching court decisions that might support her case. To protect her identity, we’ll call her Beth.

What she turned up was a German law firm’s blog post titled Medical Law: Liability for Inadequate Disclosure of Risks Associated with Cosmetic Treatment.

Written by attorney Lisa Horn of Roos Nelskamp Schumacher & Partners (RNSP) and published September 3, 2025 on the firm’s website, the post examined the Mönchengladbach judgment and its implications for physicians and patients.

Beth promptly sent us the link accompanied by a simple question: “Have you seen this?”

We hadn’t. So we translated the post into English and read every word.

If Horn’s account was accurate, we knew we had a story that the more than 200,000 readers of this newsfeed would lean into thisclose.

Horn subsequently confirmed to us that neither she nor her RNSP colleagues had been involved in the litigation. Atop her commentary was the detail we needed to verify her account: the court’s case number.

Thusly armed, we enlisted legal counsel in Germany to obtain the judgment directly from the Mönchengladbach Regional Court. The ruling hadn’t been available in the public court database we’d searched.

Three weeks later, we got a detailed account of a patient’s years-long legal battle with his dermatologist—and a judicial examination of how much physicians must disclose when prescribing finasteride for hair loss.

Nölle v. Kardorff

The case began in January 2012, when Mr. Nölle, who’d been seeing dermatologist Dr. Kardorff for routine skin cancer screenings, sought treatment for worsening hair loss.

The physician prescribed Finapil 1 mg, a generic version of Propecia. But after reading the package insert, which warned of sexual and psychological side effects, Nölle decided not to take it. Instead, he initially opted for the over-the-counter hair-loss treatment Regaine.

In August 2014, Nölle consulted a second dermatologist, who also prescribed Finapil 1 mg. According to the patient, he began taking the drug but developed testicular pain and erectile dysfunction, prompting him to discontinue it in October.

In early 2015, Nölle returned to Dr. Kardorff, who prescribed Propecia, the brand-name finasteride product. Like Finapil 1 mg, which Nölle had previously taken, it contained 1 mg of finasteride per tablet. Nölle alleged that Dr. Kardorff reassured him about the medication’s safety and suggested that switching products would resolve his earlier side effects.

Instead, Nölle claimed, his symptoms worsened. On December 2, 2015, he stopped taking Propecia on the advice of a urologist who’d told the patient his symptoms were typical of the drug.

He subsequently sued Dr. Kardorff, alleging that he continued to suffer from persistent sexual dysfunction and a range of other physical and psychological symptoms, including depression, anxiety, fatigue, cognitive dysfunction, and suicidal ideation. He maintained that the impairments had severely disrupted his professional, social and personal life.

Dr. Kardorff denied wrongdoing. He maintained that he’d adequately explained the medication’s risks, including the possibility of lasting adverse effects, and disputed the nature and extent of the patient’s alleged injuries.

Central to the dispute was whether the physician had been required to warn that sexual dysfunction might persist even after finasteride was discontinued.

A court-appointed medical expert questioned whether the scientific evidence available at the time justified requiring such a warning, citing uncertainty about the frequency and permanence of the reported effects.

But the judges saw it differently. They pointed to Propecia’s prescribing information, which had warned since 2012 that sexual dysfunction—including reduced libido, erectile dysfunction and ejaculation disorders—had been reported to persist after discontinuation.

The judges further noted that switching Nölle from generic Finapil to brand-name Propecia constituted a new treatment approach, requiring Dr. Kardorff to explain the risks again.

In the court’s view, the absence of reliable data establishing how frequently such effects occurred did not eliminate the physician’s duty to disclose them. The potential consequences were sufficiently serious that patients should have been informed, particularly because treatment for hair loss was cosmetic rather than medically necessary.

The court also emphasized that physicians could not simply rely on patients to read package inserts. They were responsible for explaining material risks themselves.

Although Dr. Kardorff’s records documented discussions of sexual side effects in 2012, they did not establish that he had warned Nölle those effects could persist after treatment ended. No such warning was documented when Propecia was prescribed in 2015. Faced with conflicting accounts from the physician and patient, the judges concluded that Kardorff had failed to prove he provided the required warning.

The judges consequently found that Nölle’s consent had not been adequately informed and held Dr. Kardorff liable in principle.

The court deferred determining the amount of compensation, explaining that further evidence would be needed to establish the nature and extent of the patient’s injuries and the damages attributable to the treatment.

In other words, the judges didn’t need to establish precisely how often persistent sexual dysfunction occurred to conclude that Nölle should have been warned of the possibility.

Horn of Plenty

“The judgment is of considerable significance for both physicians and patients,” Horn wrote in her assessment.

For physicians, she explained, the ruling underscores the need to clearly communicate and document potentially serious risks, even when their frequency is unknown—particularly when prescribing medications for cosmetic purposes. Referring patients to package inserts is not enough, and inadequate disclosure can expose doctors to substantial liability.

For patients, the attorney argued, the decision strengthens their ability to seek compensation when they were not adequately warned about risks that could result in lifelong impairment.

She suggested as well that the ruling could have repercussions beyond this particular litigation.

“It can be expected that liability cases involving finasteride and comparable medications will increasingly come before the courts in the future.”

Finasteride was originally developed by Merck & Co., Inc., and first approved by the US Food and Drug Administration in 1993 as Proscar (5 mg, for enlarged prostate), and again in 1997, as Propecia (1 mg, for hair loss).

In June 2021, Merck spun off its Organon subsidiary as an independent public company (NYSE: OGN). Founded in the Netherlands in 1923, Organon bills itself as a “global health care company dedicated to making a world of difference for women, their families and the communities they care for.” In April 2026, Mumbai, India-based Sun Pharmaceutical Industries agreed to acquire Organon in a deal worth $11.75 billion US.

Among the Merck products Organon acquired in the deal were Proscar and Propecia. To report adverse events for either finasteride product, call the Organon Service Center at (844)674-3200, or email Service_Center@Organon.com.

Anyone living in the US who suffers from PFS should also report his or her symptoms to the US FDA. Anyone living outside the US who suffers from PFS should report his or her symptoms to the US FDA as well as to his or her local DRA, as directed on our Report Your Side Effects page.

If you or a loved one are suffering from PFS, and feeling depressed or unstable, please don’t hesitate to contact the PFS Foundation as soon as possible via our Patient Support hotline: social@pfsfoundation.org

Thank you.